Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial

Documenti analoghi

• Axial Spondyloarthritis in Black Americans: An Observational Study From Five Centers in Shelby County, Tennessee
  di: Krishna Kommineni, et al.
  Pubblicazione: (2024)
• Defining Bath Ankylosing Spondylitis Disease Activity Index Cut‐off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis
  di: Stylianos Georgiadis, et al.
  Pubblicazione: (2025)
• Giant Cell Arteritis Refractory to Interleukin‐6 and Interleukin‐17 Inhibition Treated With Upadacitinib
  di: Luke S. Vest, et al.
  Pubblicazione: (2025)
• Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis
  di: Asger Reinstrup Bihlet, et al.
  Pubblicazione: (2024)
• Elevated Serum Proadrenomedullin Levels in Rheumatoid Arthritis Versus Spondyloarthritis: Insights From a Biobank Cohort
  di: Nefeli Stavroula Papastathopoulou, et al.
  Pubblicazione: (2026)